Literature DB >> 21274874

Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis.

Maria Serena Longhi1, Munther J Hussain, William W Kwok, Giorgina Mieli-Vergani, Yun Ma, Diego Vergani.   

Abstract

UNLABELLED: Effector CD4 and CD8 T cell immune responses to cytochrome P450IID6 (CYP2D6), the autoantigen of autoimmune hepatitis type 2 (AIH-2), are permitted by a numerical and functional impairment of CD4(pos) CD25(high) regulatory T cells (T-regs). We aimed to investigate whether T-regs specific for CYP2D6 immunodominant regions and restricted by the appropriate human leukocyte antigen (HLA)-DR molecule can be generated in patients with AIH-2 and can control CD4 and CD8 T cell effectors targeting identical or overlapping CYP2D6 regions. CYP2D6-specific regulatory T cells (CYP2D6 T-regs) were obtained from peptide-pulsed monocyte-depleted peripheral blood mononuclear cells of 17 patients with AIH-2, who were positive for the predisposing HLA-DR7 and/or HLA-DR3 alleles. Their antigen specificity was assessed by cytofluorimetry using HLA class II tetramers and their cytokine profile by intracellular staining. T-reg ability to suppress was ascertained by measuring reduction of CD4(pos) CD25(neg) cell proliferation/effector cytokine secretion and of CD8 T cell cytotoxicity. The most efficient suppression of effector T cell proliferation, inflammatory cytokine release, and cytotoxicity was obtained by coculturing T-regs with CYP2D6-peptide-loaded semimature dendritic cells (smDCs), and smDC-CYP2D6 T-regs also expressed high levels of FOXP3 (forkhead box P3). Possession of the appropriate HLA-DR molecule and recognition of the CYP2D6 autoantigenic sequence were critical to the synergistic smDC-CYP2D6 T-reg immunoregulatory functions, and lack of either element led to poor control of responder cell proliferation and cytokine secretion. Moreover, interferon-γ neutralization significantly boosted the suppressive ability of CYP2D6 T-regs.
CONCLUSION: T-regs generated under CYP2D6-specific conditions and cocultured with smDCs are highly effective at controlling autoreactive T cells, thus providing the basis for a powerful and tailored form of immunotherapy for AIH-2.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21274874     DOI: 10.1002/hep.24039

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

Review 1.  Cell therapies for liver diseases.

Authors:  Yue Yu; James E Fisher; Joseph B Lillegard; Brian Rodysill; Bruce Amiot; Scott L Nyberg
Journal:  Liver Transpl       Date:  2012-01       Impact factor: 5.799

Review 2.  Immune mechanisms of Concanavalin A model of autoimmune hepatitis.

Authors:  Hai-Xia Wang; Man Liu; Shun-Yan Weng; Jing-Jing Li; Chao Xie; Hong-Lin He; Wen Guan; Yun-Sheng Yuan; Jin Gao
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

Review 3.  Juvenile autoimmune hepatitis: Spectrum of the disease.

Authors:  Giuseppe Maggiore; Silvia Nastasio; Marco Sciveres
Journal:  World J Hepatol       Date:  2014-07-27

4.  A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation.

Authors:  Muhammed Yuksel; Yipeng Wang; Ningwen Tai; Jian Peng; Junhua Guo; Kathie Beland; Pascal Lapierre; Chella David; Fernando Alvarez; Isabelle Colle; Huiping Yan; Giorgina Mieli-Vergani; Diego Vergani; Yun Ma; Li Wen
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

Review 5.  Cutting edge issues in autoimmune hepatitis.

Authors:  Diego Vergani; Giorgina Mieli-Vergani
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 6.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

7.  Autoimmune hepatitis and eosinophilic granulomatosis with polyangiitis: a rare association.

Authors:  Saroj Lohani; Salik Nazir; Niranjan Tachamo; Pavani Pagolu
Journal:  BMJ Case Rep       Date:  2017-01-20

Review 8.  Autoimmune hepatitis.

Authors:  Giorgina Mieli-Vergani; Diego Vergani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-05-03       Impact factor: 46.802

Review 9.  Cell mediators of autoimmune hepatitis and their therapeutic implications.

Authors:  Aldo J Montano-Loza; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

10.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.